Functional characterization of EMSY gene amplification in human cancers

Journal of Pathology

Volumn 225, Issue 1, 2011, Pages 29-42

  Wilkerson, Paul M ^a   Dedes, Konstantin J ^a   Wetterskog, Daniel ^a   MacKay, Alan ^a   Lambros, Maryou B ^a   Mansour, Marthe ^a   Frankum, Jessica ^a   Lord, Christopher J ^a   Natrajan, Rachael ^a   Ashworth, Alan ^a   Reis Filho, Jorge S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

11q13 amplicon; biomarker; cisplatin; DNA repair; EMSY; homologous recombination; PARP inhibitors

Indexed keywords

BRCA2 PROTEIN; CISPLATIN; DNA; MESSENGER RNA; OLAPARIB; RAD51 PROTEIN; RECOMBINANT DNA;

ARTICLE; BREAST TUMOR; CELL VIABILITY; CHROMOSOME 11Q; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA DAMAGE; DNA RECOMBINATION; DNA REPAIR; EMSY GENE; ESOPHAGUS TUMOR; GENE; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENOTOXICITY; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; LUNG TUMOR; MICROARRAY ANALYSIS; MOUTH TUMOR; NEOPLASM; OVARY TUMOR; PANCREAS TUMOR; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; RNA INTERFERENCE; SENSITIVITY ANALYSIS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CHROMOSOMES, HUMAN, PAIR 11; CISPLATIN; COMPARATIVE GENOMIC HYBRIDIZATION; DNA REPAIR; DNA, NEOPLASM; ENZYME INHIBITORS; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; NUCLEAR PROTEINS; PHTHALAZINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASES; RAD51 RECOMBINASE; REPRESSOR PROTEINS; RNA, MESSENGER; RNA, NEOPLASM; RNA, SMALL INTERFERING;

EID: 79960902511     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2944     Document Type: Article

References (76)

1. Bocanegra M, Bergamaschi A, Kim YH, et al., Focal amplification and oncogene dependency of GAB2 in breast cancer. Oncogene 2010; 29: 774-779.
2. Elsheikh S, Green AR, Aleskandarany MA, et al., CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome. Breast Cancer Res Treat 2008; 109: 325-335. (Pubitemid 351644857)
3. Jirstrom K, Stendahl M, Ryden L, et al., Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification. Cancer Res 2005; 65: 8009-8016. (Pubitemid 41297281)
4. Kwek SS, Roy R, Zhou H, et al., Co-amplified genes at 8p12 and 11q13 in breast tumors cooperate with two major pathways in oncogenesis. Oncogene 2009; 28: 1892-1903.
5. Dedes KJ, Lopez-Garcia MA, Geyer FC, et al., Cortactin gene amplification and expression in breast cancer: a chromogenic in situ hybridisation and immunohistochemical study. Breast Cancer Res Treat 2010; 124: 653-666.
6. Hughes-Davies L, Huntsman D, Ruas M, et al., EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell 2003; 115: 523-535. (Pubitemid 37506042)
7. Brown LA, Johnson K, Leung S, et al., Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers. Breast Cancer Res Treat 2010; 121: 347-354.
8. Rodriguez C, Hughes-Davies L, Valles H, et al., Amplification of the BRCA2 pathway gene EMSY in sporadic breast cancer is related to negative outcome. Clin Cancer Res 2004; 10: 5785-5791. (Pubitemid 39180956)
9. Altinisik J, Karateke A, Coksuer H, et al., Expression of EMSY gene in sporadic ovarian cancer. Mol Biol Rep 2010; 38: 359-363.
10. Brown LA, Irving J, Parker R, et al., Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas. Gynecol Oncol 2006; 100: 264-270. (Pubitemid 43075259)
11. van Hattem WA, Carvalho R, Li A, et al., Amplification of EMSY gene in a subset of sporadic pancreatic adenocarcinomas. Int J Clin Exp Pathol 2008; 1: 343-351.
12. Kirkegaard T, Nielsen KV, Jensen LB, et al., Genetic alterations of CCND1 and EMSY in breast cancers. Histopathology 2008; 52: 698-705. (Pubitemid 351600044)
13. Chavali GB, Ekblad CM, Basu BP, et al., Crystal structure of the ENT domain of human EMSY. J Mol Biol 2005; 350: 964-973. (Pubitemid 40943455)
14. Garapaty S, Xu CF, Trojer P, et al., Identification and characterization of a novel nuclear protein complex involved in nuclear hormone receptor-mediated gene regulation. J Biol Chem 2009; 284: 7542-7552.
15. Raouf A, Brown L, Vrcelj N, et al., Genomic instability of human mammary epithelial cells overexpressing a truncated form of EMSY. J Natl Cancer Inst 2005; 97: 1302-1306. (Pubitemid 41535371)
16. Lips EH, Mulder L, Hannemann J, et al., Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy. Ann Oncol 2011; 22: 870-876.
17. Konstantinopoulos PA, Spentzos D, Karlan BY, et al., Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol 2010; 28: 3555-3561.
18. Bast RC Jr, Mills GB,. Personalizing therapy for ovarian cancer: BRCAness and beyond. J Clin Oncol 2010; 28: 3545-3548.
19. Stefansson OA, Jonasson JG, Johannsson OT, et al., Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes. Breast Cancer Res 2009; 11: R47.
20. Cousineau I, Belmaaza A,. EMSY overexpression disrupts the BRCA2/RAD51 pathway in the DNA-damage response: implications for chromosomal instability/recombination syndromes as checkpoint diseases. Mol Genet Genomics 2011; ePub ahead of print 16 March 2011.
21. Farmer H, McCabe N, Lord CJ, et al., Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-921. (Pubitemid 40559006)
22. Foulkes WD,. BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis. Fam Cancer 2006; 5: 135-142. (Pubitemid 43824469)
23. Barallon R, Bauer SR, Butler J, et al., Recommendation of short tandem repeat profiling for authenticating human cell lines, stem cells, and tissues. In Vitro Cell Dev Biol Anim 2010; 46: 727-732.
24. Nims RW, Sykes G, Cottrill K, et al., Short tandem repeat profiling: part of an overall strategy for reducing the frequency of cell misidentification. In Vitro Cell Dev Biol Anim 2010; 46: 811-819.
25. Marchio C, Natrajan R, Shiu KK, et al., The genomic profile of HER2-amplified breast cancers: the influence of ER status. J Pathol 2008; 216: 399-407.
26. Natrajan R, Lambros MB, Rodriguez-Pinilla SM, et al., Tiling path genomic profiling of grade 3 invasive ductal breast cancers. Clin Cancer Res 2009; 15: 2711-2722.
27. Lacroix-Triki M, Suarez PH, MacKay A, et al., Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type. J Pathol 2010; 222: 282-298.
28. Geyer FC, Weigelt B, Natrajan R, et al., Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas. J Pathol 2010; 220: 562-573.
29. Coe BP, Ylstra B, Carvalho B, et al., Resolving the resolution of array CGH. Genomics 2007; 89: 647-653. (Pubitemid 46589944)
30. Gunnarsson R, Staaf J, Jansson M, et al., Screening for copy-number alterations and loss of heterozygosity in chronic lymphocytic leukemia-a comparative study of four differently designed, high resolution microarray platforms. Genes Chromosomes Cancer 2008; 47: 697-711. (Pubitemid 351847582)
31. Tan DS, Lambros MB, Natrajan R, et al., Getting it right: designing microarray (and not 'microawry') comparative genomic hybridization studies for cancer research. Lab Invest 2007; 87: 737-754. (Pubitemid 47077258)
32. Mackay A, Tamber N, Fenwick K, et al., A high-resolution integrated analysis of genetic and expression profiles of breast cancer cell lines. Breast Cancer Res Treat 2009; 118: 481-498.
33. Natrajan R, Weigelt B, Mackay A, et al., An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. Breast Cancer Res Treat 2010; 121: 575-589.
34. Reis-Filho JS, Tutt AN,. Triple negative tumours: a critical review. Histopathology 2008; 52: 108-118. (Pubitemid 350265179)
35. Lambros MB, Simpson PT, Jones C, et al., Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent in situ hybridization. Lab Invest 2006; 86: 398-408.
36. Marchio C, Lambros MB, Gugliotta P, et al., Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. J Pathol 2009; 219: 16-24.
37. Bustin SA,. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol 2000; 25: 169-193.
38. Schmid H, Cohen CD, Henger A, et al., Validation of endogenous controls for gene expression analysis in microdissected human renal biopsies. Kidney Int 2003; 64: 356-360. (Pubitemid 36714191)
39. Lambros MB, Natrajan R, Geyer FC, et al., PPM1D gene amplification and overexpression in breast cancer: a qRT-PCR and chromogenic in situ hybridization study. Mod Pathol 2010; 23: 1334-1345.
40. Schildknecht S, Pape R, Muller N, et al., Neuroprotection by minocycline caused by direct and specific scavenging of peroxynitrite. J Biol Chem 2011; 286: 4991-5002.
41. Turner NC, Lord CJ, Iorns E, et al., A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J 2008; 27: 1368-1377. (Pubitemid 351655175)
42. Iorns E, Lord CJ, Ashworth A,. Parallel RNAi and compound screens identify the PDK1 pathway as a target for tamoxifen sensitization. Biochem J 2009; 417: 361-370.
43. Iorns E, Lord CJ, Grigoriadis A, et al., Integrated functional, gene expression and genomic analysis for the identification of cancer targets. PLoS One 2009; 4: e5120.
44. Martin SA, Hewish M, Sims D, et al., Parallel high-throughput RNA interference screens identify PINK1 as a potential therapeutic target for the treatment of DNA mismatch repair-deficient cancers. Cancer Res 2011; 71: 1836-1848.
45. McCabe N, Turner NC, Lord CJ, et al., Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006; 66: 8109-8115. (Pubitemid 44299177)
46. Dedes KJ, Wetterskog D, Mendes-Pereira AM, et al., PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Sci Transl Med 2010; 2: 53ra75.
47. Mendes-Pereira AM, Martin SA, Brough R, et al., Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 2009; 1: 315-322.
48. Bonner WM, Redon CE, Dickey JS, et al., γH2AX and cancer. Nat Rev Cancer 2008; 8: 957-967.
49. Hoeijmakers JH,. Genome maintenance mechanisms for preventing cancer. Nature 2001; 411: 366-374. (Pubitemid 32467046)
50. Edwards SL, Brough R, Lord CJ, et al., Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008; 451: 1111-1115. (Pubitemid 351317441)
51. Bhattacharyya A, Ear US, Koller BH, et al., The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 2000; 275: 23899-23903. (Pubitemid 30624678)
52. Hastak K, Alli E, Ford JM,. Synergistic chemosensitivity of triple-negative breast cancer cell lines to PARP inhibition, gemcitabine and cisplatin. Cancer Res 2010; 70: 7970-7980.
53. Bernard-Pierrot I, Gruel N, Stransky N, et al., Characterization of the recurrent 8p11-12 amplicon identifies PPAPDC1B, a phosphatase protein, as a new therapeutic target in breast cancer. Cancer Res 2008; 68: 7165-7175.
54. Shiu KK, Natrajan R, Geyer FC, et al., DNA amplifications in breast cancer: genotypic-phenotypic correlations. Future Oncol 2010; 6: 967-984.
55. Chen F, Nastasi A, Shen Z, et al., Cell cycle-dependent protein expression of mammalian homologs of yeast DNA double-strand break repair genes Rad51 and Rad52. Mutat Res 1997; 384: 205-211. (Pubitemid 27394245)
56. Yamamoto A, Taki T, Yagi H, et al., Cell cycle-dependent expression of the mouse Rad51 gene in proliferating cells. Mol Gen Genet 1996; 251: 1-12.
57. Xia SJ, Shammas MA, Shmookler Reis RJ,. Elevated recombination in immortal human cells is mediated by HsRAD51 recombinase. Mol Cell Biol 1997; 17: 7151-7158. (Pubitemid 27505945)
58. Bertwistle D, Swift S, Marston NJ, et al., Nuclear location and cell cycle regulation of the BRCA2 protein. Cancer Res 1997; 57: 5485-5488. (Pubitemid 28006752)
59. Su LK, Wang SC, Qi Y, et al., Characterization of BRCA2: temperature sensitivity of detection and cell-cycle regulated expression. Oncogene 1998; 17: 2377-2381. (Pubitemid 28515391)
60. Tan DS, Lambros MB, Rayter S, et al., PPM1D is a potential therapeutic target in ovarian clear cell carcinomas. Clin Cancer Res 2009; 15: 2269-2280.
61. Tutt A, Ashworth A,. The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. Trends Mol Med 2002; 8: 571-576. (Pubitemid 35408215)
62. Moynahan ME, Pierce AJ, Jasin M,. BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell 2001; 7: 263-272. (Pubitemid 32206494)
63. Tutt A, Bertwistle D, Valentine J, et al., Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences. EMBO J 2001; 20: 4704-4716. (Pubitemid 32848624)
64. Powell SN, Kachnic LA,. Therapeutic exploitation of tumor cell defects in homologous recombination. Anticancer Agents Med Chem 2008; 8: 448-460. (Pubitemid 351761429)
65. Evers B, Drost R, Schut E, et al., Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin Cancer Res 2008; 14: 3916-3925.
66. Tutt A, Robson M, Garber JE, et al., Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010; 376: 235-244.
67. Audeh MW, Carmichael J, Penson RT, et al., Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010; 376: 245-251.
68. Kortmann U, McAlpine JN, Xue H, et al., Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts. Clin Cancer Res 2011; 17: 783-791.
69. Bryant HE, Schultz N, Thomas HD, et al., Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434: 913-917. (Pubitemid 40559005)
70. Rottenberg S, Jaspers JE, Kersbergen A, et al., High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci USA 2008; 105: 17079-17084.
71. Fong PC, Boss DS, Yap TA, et al., Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123-134.
72. Shen WH, Balajee AS, Wang J, et al., Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 2007; 128: 157-170. (Pubitemid 46048887)
73. Villarroel MC, Rajeshkumar NV, Garrido-Laguna I, et al., Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol Cancer Ther 2011; 10: 3-8.
74. Buisson R, Dion-Cote AM, Coulombe Y, et al., Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination. Nat Struct Mol Biol 2010; 17: 1247-1254.
75. Turner N, Tutt A, Ashworth A,. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004; 4: 814-819. (Pubitemid 39331153)
76. Neve RM, Chin K, Fridlyand J, et al., A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006; 10: 515-527. (Pubitemid 44854747)